A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days

Author:

Kobayashi Eiji,Mizukoshi Eishiro,Kishi Hiroyuki,Ozawa Tatsuhiko,Hamana Hiroshi,Nagai Terumi,Nakagawa Hidetoshi,Jin Aishun,Kaneko Shuichi,Muraguchi Atsushi

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Parsing digital or analog TCR performance through piconewton forces;Science Advances;2024-08-16

2. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors;Journal for ImmunoTherapy of Cancer;2024-07

3. Tumor Antigens beyond the Human Exome;International Journal of Molecular Sciences;2024-04-25

4. Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

5. The intersection of virus infection and liver disease: A comprehensive review of pathogenesis, diagnosis, and treatment;WIREs Mechanisms of Disease;2024-01-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3